CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL.Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
Further to our recent discussions, we are pleased to offer you employment at Cardiol Therapeutics Inc. (the “Corporation”) as the Chief Financial Officer, on a part-time basis on the following terms and conditions.
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] EXCLUSIVE SUPPLY AGREEMENTExclusive Supply Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE SUPPLY AGREEMENT (this “Agreement”) is made as of September 28, 2018 (the “Effective Date”), by and between Noramco, Inc., a Georgia corporation, with offices at 500 Swedes Landing Road, Wilmington, Delaware 19801, USA (“Noramco”), and Cardiol Therapeutics Inc., an Ontario corporation located at 2275 Upper Middle Road East, Suite 101, Oakville, ON, Canada, L6H 0C3 (“Buyer”). Noramco and Buyer may be referred to herein each as a “Party” or together as the “Parties”, as the context may require.
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- CHRISTOPHER WADDICK (the “Employee”) (Each a “Party” and together the “Parties”)Employment Agreement Addendum • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated April 16, 2018, including the addendum agreement dated December 23, 2021 (the “Employment Agreement”);
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- CHRISTOPHER WADDICK (the “Employee”) (Each a “Party” and together the “Parties”)Employment Agreement Addendum • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated April 16, 2018 (the “Employment Agreement”);
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K DUE TO PERSONAL PRIVACY CONCERNS. REDACTED INFORMATION IS INDICATED BY: [***] EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
EMPLOYMENT AGREEMENTEmployment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on May 30th 2022 by and between Cardiol Therapeutics USA Inc. (the “Company”) and Andrew Warwick Hamer (the “Executive”) (collectively, the “Parties”).
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- BERNARD LIM (the “Employee”) (Each a “Party” and together the “Parties”).Employment Agreement Addendum • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated December 3, 2020 (the “Employment Agreement”);
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] DEVELOPMENT AGREEMENTDevelopment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements set forth herein, the Parties agree as follows:
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] LICENSE AGREEMENTLicense Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • Alberta
This License Agreement (“License Agreement”) is made this 20th day of January, 2017 (the “Effective Date”) by and between Meros Polymers Inc., a company incorporated under the laws of Alberta, with a principal place of business at 1700 Enbridge Centre, 10175 — 101 Street NW, Edmonton, Alberta T5J 0H3, Canada (“Meros”), and Cardiol Therapeutics Inc. (“Cardiol”) a company incorporated under the laws of Ontario, with a principal place of business at 2275 Upper Middle Road East, Suite 101, Oakville, Ontario, L6H 0C3 (together with any Affiliate to which this Agreement may be assigned pursuant to Section 18.8 hereof). For purposes hereof, Meros and Cardiol. are each referred to hereinafter individually as a “Party” and together as the “Parties”. For purposes hereof, capitalized terms not otherwise defined herein shall have the meanings assigned such terms in Article 1 hereof, or as otherwise indicated.
PERSONAL AND CONFIDENTIALEmployment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
Further to our recent discussions, we are pleased to offer you employment at Cardiol Therapeutics Inc. (the “Corporation”) as Chief Operating Officer on the following terms and conditions.
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] EXCLUSIVE MASTER SERVICES AGREEMENTExclusive Master Services Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
Dalton Chemical Laboratories, Inc. o/a Dalton Pharma Services, a corporation incorporated under the laws of the Province of Ontario, Canada whose principal operations are located at: 349 Wildcat Road, Toronto, ON, M3J 253, Canada together with its subsidiaries and affiliates (as defined below), (hereinafter referred to as “CONTRACTOR”)
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- DAVID ELSLEY (the “Employee”) (Each a “Party” and together the “Parties”)Employment Agreement Addendum • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated January 19, 2017 (the “Employment Agreement”);
